ID   A0A024RCX5_HUMAN        Unreviewed;       164 AA.
AC   A0A024RCX5;
DT   09-JUL-2014, integrated into UniProtKB/TrEMBL.
DT   09-JUL-2014, sequence version 1.
DT   25-APR-2018, entry version 39.
DE   SubName: Full=Cyclin-dependent kinase inhibitor 1A (P21, Cip1), isoform CRA_a {ECO:0000313|EMBL:EAX03907.1};
GN   Name=CDKN1A {ECO:0000313|EMBL:EAX03907.1};
GN   ORFNames=hCG_15367 {ECO:0000313|EMBL:EAX03907.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAX03907.1};
RN   [1] {ECO:0000313|EMBL:EAX03907.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D.,
RA   Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q.,
RA   Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G.,
RA   Thomas P.D., Zhang J., Gabor Miklos G.L., Nelson C., Broder S.,
RA   Clark A.G., Nadeau J., McKusick V.A., Zinder N., Levine A.J.,
RA   Roberts R.J., Simon M., Slayman C., Hunkapiller M., Bolanos R.,
RA   Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A.,
RA   Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K.,
RA   Remington K., Abu-Threideh J., Beasley E., Biddick K., Bonazzi V.,
RA   Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z.,
RA   Guan P., Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A.,
RA   Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V.,
RA   Milshina N., Moore H.M., Naik A.K., Narayan V.A., Neelam B.,
RA   Nusskern D., Rusch D.B., Salzberg S., Shao W., Shue B., Sun J.,
RA   Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C.,
RA   Yao A., Ye J., Zhan M., Zhang W., Zhang H., Zhao Q., Zheng L.,
RA   Zhong F., Zhong W., Zhu S., Zhao S., Gilbert D., Baumhueter S.,
RA   Spier G., Carter C., Cravchik A., Woodage T., Ali F., An H., Awe A.,
RA   Baldwin D., Baden H., Barnstead M., Barrow I., Beeson K., Busam D.,
RA   Carver A., Center A., Cheng M.L., Curry L., Danaher S., Davenport L.,
RA   Desilets R., Dietz S., Dodson K., Doup L., Ferriera S., Garg N.,
RA   Gluecksmann A., Hart B., Haynes J., Haynes C., Heiner C., Hladun S.,
RA   Hostin D., Houck J., Howland T., Ibegwam C., Johnson J., Kalush F.,
RA   Kline L., Koduru S., Love A., Mann F., May D., McCawley S.,
RA   McIntosh T., McMullen I., Moy M., Moy L., Murphy B., Nelson K.,
RA   Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N.,
RA   Tse S., Vech C., Wang G., Wetter J., Williams S., Williams M.,
RA   Windsor S., Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F.,
RA   Guigo R., Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A.,
RA   Mi H., Lazareva B., Hatton T., Narechania A., Diemer K.,
RA   Muruganujan A., Guo N., Sato S., Bafna V., Istrail S., Lippert R.,
RA   Schwartz R., Walenz B., Yooseph S., Allen D., Basu A., Baxendale J.,
RA   Blick L., Caminha M., Carnes-Stine J., Caulk P., Chiang Y.H.,
RA   Coyne M., Dahlke C., Mays A., Dombroski M., Donnelly M., Ely D.,
RA   Esparham S., Fosler C., Gire H., Glanowski S., Glasser K., Glodek A.,
RA   Gorokhov M., Graham K., Gropman B., Harris M., Heil J., Henderson S.,
RA   Hoover J., Jennings D., Jordan C., Jordan J., Kasha J., Kagan L.,
RA   Kraft C., Levitsky A., Lewis M., Liu X., Lopez J., Ma D., Majoros W.,
RA   McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N., Nodell M.,
RA   Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAX03907.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; CH471081; EAX03905.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX03907.1; -; Genomic_DNA.
DR   RefSeq; NP_000380.1; NM_000389.4.
DR   RefSeq; NP_001207706.1; NM_001220777.1.
DR   RefSeq; NP_001207707.1; NM_001220778.1.
DR   RefSeq; NP_510867.1; NM_078467.2.
DR   UniGene; Hs.370771; -.
DR   UniGene; Hs.732576; -.
DR   GeneID; 1026; -.
DR   KEGG; hsa:1026; -.
DR   CTD; 1026; -.
DR   EuPathDB; HostDB:ENSG00000124762.13; -.
DR   eggNOG; KOG4743; Eukaryota.
DR   eggNOG; ENOG410XXN5; LUCA.
DR   KO; K06625; -.
DR   OMA; FAWERVW; -.
DR   OrthoDB; EOG091G19PZ; -.
DR   ChiTaRS; CDKN1A; human.
DR   GenomeRNAi; 1026; -.
DR   Bgee; ENSG00000124762; -.
DR   GO; GO:0000307; C:cyclin-dependent protein kinase holoenzyme complex; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0030332; F:cyclin binding; IEA:Ensembl.
DR   GO; GO:0004861; F:cyclin-dependent protein serine/threonine kinase inhibitor activity; IEA:Ensembl.
DR   GO; GO:0016301; F:kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; IEA:Ensembl.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0034605; P:cellular response to heat; IEA:Ensembl.
DR   GO; GO:0071493; P:cellular response to UV-B; IEA:Ensembl.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IEA:Ensembl.
DR   GO; GO:0060574; P:intestinal epithelial cell maturation; IEA:Ensembl.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0071850; P:mitotic cell cycle arrest; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IEA:Ensembl.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IEA:Ensembl.
DR   GO; GO:0043068; P:positive regulation of programmed cell death; IEA:Ensembl.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:2000278; P:regulation of DNA biosynthetic process; IEA:Ensembl.
DR   GO; GO:0033158; P:regulation of protein import into nucleus, translocation; IEA:Ensembl.
DR   GO; GO:0090399; P:replicative senescence; IEA:Ensembl.
DR   GO; GO:0046685; P:response to arsenic-containing substance; IEA:Ensembl.
DR   GO; GO:0051412; P:response to corticosterone; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0055093; P:response to hyperoxia; IEA:Ensembl.
DR   GO; GO:0010243; P:response to organonitrogen compound; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0010165; P:response to X-ray; IEA:Ensembl.
DR   InterPro; IPR003175; CDI.
DR   InterPro; IPR029841; CDKN1A_vertebrate.
DR   PANTHER; PTHR10265; PTHR10265; 1.
DR   PANTHER; PTHR10265:SF16; PTHR10265:SF16; 1.
DR   Pfam; PF02234; CDI; 1.
PE   4: Predicted;
KW   Kinase {ECO:0000313|EMBL:EAX03907.1};
KW   Transferase {ECO:0000313|EMBL:EAX03907.1}.
SQ   SEQUENCE   164 AA;  18119 MW;  98D1E7C519ADFCA9 CRC64;
     MSEPAGDVRQ NPCGSKACRR LFGPVDSEQL SRDCDALMAG CIQEARERWN FDFVTETPLE
     GDFAWERVRG LGLPKLYLPT GPRRGRDELG GGRRPGTSPA LLQGTAEEDH VDLSLSCTLV
     PRSGEQAEGS PGGPGDSQGR KRRQTSMTDF YHSKRRLIFS KRKP
//
ID   CDN1A_HUMAN             Reviewed;         164 AA.
AC   P38936; Q14010; Q6FI05; Q9BUT4;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   25-APR-2018, entry version 206.
DE   RecName: Full=Cyclin-dependent kinase inhibitor 1;
DE   AltName: Full=CDK-interacting protein 1;
DE   AltName: Full=Melanoma differentiation-associated protein 6;
DE            Short=MDA-6;
DE   AltName: Full=p21;
GN   Name=CDKN1A; Synonyms=CAP20, CDKN1, CIP1, MDA6, PIC1, SDI1, WAF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND INDUCTION.
RX   PubMed=8242751; DOI=10.1016/0092-8674(93)90499-G;
RA   Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J.;
RT   "The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1
RT   cyclin-dependent kinases.";
RL   Cell 75:805-816(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND INDUCTION.
RX   PubMed=8242752; DOI=10.1016/0092-8674(93)90500-P;
RA   El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R.,
RA   Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B.;
RT   "WAF1, a potential mediator of p53 tumor suppression.";
RL   Cell 75:817-825(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8259214; DOI=10.1038/366701a0;
RA   Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., Beach D.;
RT   "p21 is a universal inhibitor of cyclin kinases.";
RL   Nature 366:701-704(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Jiang H., Fisher P.B.;
RT   "Use of a sensitive and efficient subtraction hybridization protocol
RT   for the identification of genes differentially regulated during the
RT   induction of differentiation in human melanoma cells.";
RL   Mol. Cell. Differ. 1:285-299(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7753561;
RA   Jiang H., Lin J., Su Z.Z., Herlyn M., Kerbel R.S., Weissman B.E.,
RA   Welch D.R., Fisher P.B.;
RT   "The melanoma differentiation-associated gene mda-6, which encodes the
RT   cyclin-dependent kinase inhibitor p21, is differentially expressed
RT   during growth, differentiation and progression in human melanoma
RT   cells.";
RL   Oncogene 10:1855-1864(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8125163; DOI=10.1006/excr.1994.1063;
RA   Noda A., Ning Y., Venable S.F., Pereira-Smith O.M., Smith J.R.;
RT   "Cloning of senescent cell-derived inhibitors of DNA synthesis using
RT   an expression screen.";
RL   Exp. Cell Res. 211:90-98(1994).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-31.
RX   PubMed=7655464; DOI=10.1093/hmg/4.6.1089;
RA   Mousses S., Oezcelik H., Lee P.D., Malkin D., Bull S.B.,
RA   Andrulis I.L.;
RT   "Two variants of the CIP1/WAF1 gene occur together and are associated
RT   with human cancer.";
RL   Hum. Mol. Genet. 4:1089-1092(1995).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ARG-31.
RG   NIEHS SNPs program;
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H.,
RA   Maruyama Y., Matsuo K., Minami K., Mitsubori M., Mori M.,
RA   Morishita R., Murase A., Nishikawa A., Nishikawa S., Okamoto T.,
RA   Sakagami N., Sakamoto Y., Sasaki Y., Seki T., Sono S., Sugiyama A.,
RA   Sumiya T., Takayama T., Takayama Y., Takeda H., Togashi T., Yahata K.,
RA   Yamada H., Yanagisawa Y., Endo Y., Imamoto F., Kisu Y., Tanaka S.,
RA   Isogai T., Imai J., Watanabe S., Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in
RT   vitro-expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ARG-31.
RC   TISSUE=Eye, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [15]
RP   PROTEIN SEQUENCE OF 2-16, ACETYLATION AT SER-2, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=15574338; DOI=10.1016/j.molcel.2004.11.011;
RA   Chen X., Chi Y., Bloecher A., Aebersold R., Clurman B.E.,
RA   Roberts J.M.;
RT   "N-acetylation and ubiquitin-independent proteasomal degradation of
RT   p21(Cip1).";
RL   Mol. Cell 16:839-847(2004).
RN   [16]
RP   PROTEIN SEQUENCE OF 136-148, PHOSPHORYLATION AT THR-145; SER-146 AND
RP   SER-160, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=10753973; DOI=10.1074/jbc.275.15.11529;
RA   Scott M.T., Morrice N., Ball K.L.;
RT   "Reversible phosphorylation at the C-terminal regulatory domain of
RT   p21(Waf1/Cip1) modulates proliferating cell nuclear antigen binding.";
RL   J. Biol. Chem. 275:11529-11537(2000).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CDK4 AND CCND1 IN
RP   THE CYCLIN D-CDK4-CDKN1A COMPLEX.
RX   PubMed=9106657; DOI=10.1101/gad.11.7.847;
RA   LaBaer J., Garrett M.D., Stevenson L.F., Slingerland J.M., Sandhu C.,
RA   Chou H.S., Fattaey A., Harlow E.;
RT   "New functional activities for the p21 family of CDK inhibitors.";
RL   Genes Dev. 11:847-862(1997).
RN   [18]
RP   INTERACTION WITH PSMA3.
RX   PubMed=11350925; DOI=10.1093/emboj/20.10.2367;
RA   Touitou R., Richardson J., Bose S., Nakanishi M., Rivett J.,
RA   Allday M.J.;
RT   "A degradation signal located in the C-terminus of p21WAF1/CIP1 is a
RT   binding site for the C8 alpha-subunit of the 20S proteasome.";
RL   EMBO J. 20:2367-2375(2001).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH PCNA.
RX   PubMed=11595739; DOI=10.1074/jbc.M106990200;
RA   Ducoux M., Urbach S., Baldacci G., Huebscher U., Koundrioukoff S.,
RA   Christensen J., Hughes P.;
RT   "Mediation of proliferating cell nuclear antigen (PCNA)-dependent DNA
RT   replication through a conserved p21(Cip1)-like PCNA-binding motif
RT   present in the third subunit of human DNA polymerase delta.";
RL   J. Biol. Chem. 276:49258-49266(2001).
RN   [20]
RP   PHOSPHORYLATION AT THR-145, MUTAGENESIS OF THR-145 AND SER-146, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=11463845; DOI=10.1128/MCB.21.16.5644-5657.2001;
RA   Roessig L., Jadidi A.S., Urbich C., Badorff C., Zeiher A.M.,
RA   Dimmeler S.;
RT   "Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and
RT   proliferation of endothelial cells.";
RL   Mol. Cell. Biol. 21:5644-5657(2001).
RN   [21]
RP   PHOSPHORYLATION AT THR-145 BY PIM1, SUBCELLULAR LOCATION, AND
RP   INTERACTION WITH PIM1.
RX   PubMed=12431783; DOI=10.1016/S0167-4889(02)00347-6;
RA   Wang Z., Bhattacharya N., Mixter P.F., Wei W., Sedivy J.,
RA   Magnuson N.S.;
RT   "Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1
RT   kinase.";
RL   Biochim. Biophys. Acta 1593:45-55(2002).
RN   [22]
RP   UBIQUITINATION AT SER-2.
RX   PubMed=15226418; DOI=10.1128/MCB.24.14.6140-6150.2004;
RA   Coulombe P., Rodier G., Bonneil E., Thibault P., Meloche S.;
RT   "N-Terminal ubiquitination of extracellular signal-regulated kinase 3
RT   and p21 directs their degradation by the proteasome.";
RL   Mol. Cell. Biol. 24:6140-6150(2004).
RN   [23]
RP   PHOSPHORYLATION AT THR-145.
RX   PubMed=16982699; DOI=10.1128/MCB.00201-06;
RA   Heron-Milhavet L., Franckhauser C., Rana V., Berthenet C., Fisher D.,
RA   Hemmings B.A., Fernandez A., Lamb N.J.;
RT   "Only Akt1 is required for proliferation, while Akt2 promotes cell
RT   cycle exit through p21 binding.";
RL   Mol. Cell. Biol. 26:8267-8280(2006).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-130, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [25]
RP   UBIQUITINATION, DOMAIN PIP-BOX K+4 MOTIF, INTERACTION WITH PCNA,
RP   MUTAGENESIS OF SER-114 AND 144-GLN--PHE-150, AND PHOSPHORYLATION AT
RP   SER-114.
RX   PubMed=18794347; DOI=10.1101/gad.1676108;
RA   Abbas T., Sivaprasad U., Terai K., Amador V., Pagano M., Dutta A.;
RT   "PCNA-dependent regulation of p21 ubiquitylation and degradation via
RT   the CRL4Cdt2 ubiquitin ligase complex.";
RL   Genes Dev. 22:2496-2506(2008).
RN   [26]
RP   UBIQUITINATION.
RX   PubMed=18794348; DOI=10.1101/gad.1703708;
RA   Kim Y., Starostina N.G., Kipreos E.T.;
RT   "The CRL4Cdt2 ubiquitin ligase targets the degradation of p21Cip1 to
RT   control replication licensing.";
RL   Genes Dev. 22:2507-2519(2008).
RN   [27]
RP   UBIQUITINATION, DOMAIN PIP-BOX K+4 MOTIF, MUTAGENESIS OF
RP   147-MET--TYR-151 AND 154-LYS--ARG-156, AND INTERACTION WITH PCNA.
RX   PubMed=18703516; DOI=10.1074/jbc.M806045200;
RA   Nishitani H., Shiomi Y., Iida H., Michishita M., Takami T.,
RA   Tsurimoto T.;
RT   "CDK inhibitor p21 is degraded by a proliferating cell nuclear
RT   antigen-coupled Cul4-DDB1Cdt2 pathway during S phase and after UV
RT   irradiation.";
RL   J. Biol. Chem. 283:29045-29052(2008).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-130, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [29]
RP   REVIEW ON DNA REPAIR, AND INTERACTION WITH CDK2.
RX   PubMed=19445729; DOI=10.1186/1747-1028-4-9;
RA   Satyanarayana A., Kaldis P.;
RT   "A dual role of Cdk2 in DNA damage response.";
RL   Cell Div. 4:9-9(2009).
RN   [30]
RP   UBIQUITINATION, AND INTERACTION WITH MKRN1.
RX   PubMed=19536131; DOI=10.1038/emboj.2009.164;
RA   Lee E.-W., Lee M.-S., Camus S., Ghim J., Yang M.-R., Oh W., Ha N.-C.,
RA   Lane D.P., Song J.;
RT   "Differential regulation of p53 and p21 by MKRN1 E3 ligase controls
RT   cell cycle arrest and apoptosis.";
RL   EMBO J. 28:2100-2113(2009).
RN   [31]
RP   UBIQUITINATION.
RX   PubMed=19332548; DOI=10.1074/jbc.M808810200;
RA   Stuart S.A., Wang J.Y.;
RT   "Ionizing radiation induces ATM-independent degradation of p21Cip1 in
RT   transformed cells.";
RL   J. Biol. Chem. 284:15061-15070(2009).
RN   [32]
RP   PHOSPHORYLATION AT THR-145 BY PIM2.
RX   PubMed=20307683; DOI=10.1016/j.biocel.2010.03.012;
RA   Wang Z., Zhang Y., Gu J.J., Davitt C., Reeves R., Magnuson N.S.;
RT   "Pim-2 phosphorylation of p21(Cip1/WAF1) enhances its stability and
RT   inhibits cell proliferation in HCT116 cells.";
RL   Int. J. Biochem. Cell Biol. 42:1030-1038(2010).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [34]
RP   UBIQUITINATION BY RNF114.
RX   PubMed=23645206; DOI=10.1038/cdd.2013.33;
RA   Han J., Kim Y.L., Lee K.W., Her N.G., Ha T.K., Yoon S., Jeong S.I.,
RA   Lee J.H., Kang M.J., Lee M.G., Ryu B.K., Baik J.H., Chi S.G.;
RT   "ZNF313 is a novel cell cycle activator with an E3 ligase activity
RT   inhibiting cellular senescence by destabilizing p21(WAF1.).";
RL   Cell Death Differ. 20:1055-1067(2013).
RN   [35]
RP   FUNCTION, INTERACTION WITH STK11 AND NUAK1, PHOSPHORYLATION AT THR-80
RP   AND SER-146, AND MUTAGENESIS OF THR-80 AND SER-146.
RX   PubMed=25329316; DOI=10.1371/journal.pgen.1004721;
RA   Esteve-Puig R., Gil R., Gonzalez-Sanchez E., Bech-Serra J.J.,
RA   Grueso J., Hernandez-Losa J., Moline T., Canals F., Ferrer B.,
RA   Cortes J., Bastian B., Cajal S.R.Y., Martin-Caballero J., Flores J.M.,
RA   Vivancos A., Garcia-Patos V., Recio J.A.;
RT   "A mouse model uncovers LKB1 as an UVB-induced DNA damage sensor
RT   mediating CDKN1A (p21WAF1/CIP1) degradation.";
RL   PLoS Genet. 10:E1004721-E1004721(2014).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 139-160 IN COMPLEX WITH PCNA.
RX   PubMed=8861913; DOI=10.1016/S0092-8674(00)81347-1;
RA   Gulbis J.M., Kelman Z., Hurwitz J., O'Donnell M., Kuriyan J.;
RT   "Structure of the C-terminal region of p21(WAF1/CIP1) complexed with
RT   human PCNA.";
RL   Cell 87:297-306(1996).
CC   -!- FUNCTION: May be involved in p53/TP53 mediated inhibition of
CC       cellular proliferation in response to DNA damage. Binds to and
CC       inhibits cyclin-dependent kinase activity, preventing
CC       phosphorylation of critical cyclin-dependent kinase substrates and
CC       blocking cell cycle progression. Functions in the nuclear
CC       localization and assembly of cyclin D-CDK4 complex and promotes
CC       its kinase activity towards RB1. At higher stoichiometric ratios,
CC       inhibits the kinase activity of the cyclin D-CDK4 complex.
CC       Inhibits DNA synthesis by DNA polymerase delta by competing with
CC       POLD3 for PCNA binding (PubMed:11595739).
CC       {ECO:0000269|PubMed:11595739, ECO:0000269|PubMed:8242751,
CC       ECO:0000269|PubMed:9106657}.
CC   -!- SUBUNIT: Interacts with HDAC1; the interaction is prevented by
CC       competitive binding of C10orf90/FATS to HDAC1 facilitating
CC       acetylation and protein stabilization of CDKN1A/p21 (By
CC       similarity). Interacts with MKRN1 (PubMed:19536131). Interacts
CC       with PSMA3 (PubMed:11350925). Interacts with PCNA
CC       (PubMed:11595739, PubMed:18794347, PubMed:18703516,
CC       PubMed:8861913). Component of the ternary complex, cyclin D-CDK4-
CC       CDKN1A. Interacts (via its N-terminal domain) with CDK4; the
CC       interaction promotes the assembly of the cyclin D-CDK4 complex,
CC       its nuclear translocation and promotes the cyclin D-dependent
CC       enzyme activity of CDK4 (PubMed:9106657). Binding to CDK2 leads to
CC       CDK2/cyclin E inactivation at the G1-S phase DNA damage
CC       checkpoint, thereby arresting cells at the G1-S transition during
CC       DNA repair (PubMed:19445729). Interacts with PIM1
CC       (PubMed:12431783). Interacts with STK11 and NUAK1
CC       (PubMed:25329316). {ECO:0000250|UniProtKB:P39689,
CC       ECO:0000269|PubMed:11350925, ECO:0000269|PubMed:11595739,
CC       ECO:0000269|PubMed:12431783, ECO:0000269|PubMed:18703516,
CC       ECO:0000269|PubMed:18794347, ECO:0000269|PubMed:19445729,
CC       ECO:0000269|PubMed:19536131, ECO:0000269|PubMed:25329316,
CC       ECO:0000269|PubMed:8861913, ECO:0000269|PubMed:9106657}.
CC   -!- INTERACTION:
CC       P27958:- (xeno); NbExp=3; IntAct=EBI-375077, EBI-6377335;
CC       P78396:CCNA1; NbExp=3; IntAct=EBI-375077, EBI-375065;
CC       P20248:CCNA2; NbExp=3; IntAct=EBI-375077, EBI-457097;
CC       P14635:CCNB1; NbExp=2; IntAct=EBI-375077, EBI-495332;
CC       P24385:CCND1; NbExp=15; IntAct=EBI-375077, EBI-375001;
CC       P30279:CCND2; NbExp=14; IntAct=EBI-375077, EBI-748789;
CC       P30281:CCND3; NbExp=17; IntAct=EBI-375077, EBI-375013;
CC       P24864:CCNE1; NbExp=9; IntAct=EBI-375077, EBI-519526;
CC       O96020:CCNE2; NbExp=4; IntAct=EBI-375077, EBI-375033;
CC       O75419:CDC45; NbExp=2; IntAct=EBI-375077, EBI-374969;
CC       Q99741:CDC6; NbExp=2; IntAct=EBI-375077, EBI-374862;
CC       P06493:CDK1; NbExp=3; IntAct=EBI-375077, EBI-444308;
CC       O94921:CDK14; NbExp=8; IntAct=EBI-375077, EBI-1043945;
CC       P24941:CDK2; NbExp=26; IntAct=EBI-375077, EBI-375096;
CC       Q00526:CDK3; NbExp=4; IntAct=EBI-375077, EBI-1245761;
CC       P11802:CDK4; NbExp=5; IntAct=EBI-375077, EBI-295644;
CC       Q00535:CDK5; NbExp=4; IntAct=EBI-375077, EBI-1041567;
CC       P03129:E7 (xeno); NbExp=6; IntAct=EBI-375077, EBI-866453;
CC       Q9UKT9:IKZF3; NbExp=3; IntAct=EBI-375077, EBI-747204;
CC       Q15323:KRT31; NbExp=5; IntAct=EBI-375077, EBI-948001;
CC       Q9UHC7:MKRN1; NbExp=5; IntAct=EBI-375077, EBI-373524;
CC       Q9BQ15:NABP2; NbExp=7; IntAct=EBI-375077, EBI-2120336;
CC       P12004:PCNA; NbExp=29; IntAct=EBI-375077, EBI-358311;
CC       Q6FI35:PCNA; NbExp=2; IntAct=EBI-375077, EBI-8469539;
CC       Q9UQR0-1:SCML2; NbExp=3; IntAct=EBI-375077, EBI-16087037;
CC       Q96FS4:SIPA1; NbExp=2; IntAct=EBI-375077, EBI-1054981;
CC       P63208:SKP1; NbExp=3; IntAct=EBI-375077, EBI-307486;
CC       Q13309:SKP2; NbExp=2; IntAct=EBI-375077, EBI-456291;
CC       P15884:TCF4; NbExp=3; IntAct=EBI-375077, EBI-533224;
CC       Q8IYF3:TEX11; NbExp=4; IntAct=EBI-375077, EBI-742397;
CC       P04637:TP53; NbExp=3; IntAct=EBI-375077, EBI-366083;
CC       Q13077:TRAF1; NbExp=3; IntAct=EBI-375077, EBI-359224;
CC       Q9BYV2:TRIM54; NbExp=5; IntAct=EBI-375077, EBI-2130429;
CC       Q61187:Tsg101 (xeno); NbExp=3; IntAct=EBI-375077, EBI-1202711;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus.
CC   -!- TISSUE SPECIFICITY: Expressed in all adult tissues, with 5-fold
CC       lower levels observed in the brain.
CC   -!- INDUCTION: Activated by p53/TP53, mezerein (antileukemic compound)
CC       and IFNB1. Repressed by HDAC1. {ECO:0000269|PubMed:8242751,
CC       ECO:0000269|PubMed:8242752}.
CC   -!- DOMAIN: The PIP-box K+4 motif mediates both the interaction with
CC       PCNA and the recruitment of the DCX(DTL) complex: while the PIP-
CC       box interacts with PCNA, the presence of the K+4 submotif,
CC       recruits the DCX(DTL) complex, leading to its ubiquitination.
CC   -!- DOMAIN: The C-terminal is required for nuclear localization of the
CC       cyclin D-CDK4 complex.
CC   -!- PTM: Phosphorylation of Thr-145 by Akt or of Ser-146 by PKC
CC       impairs binding to PCNA. Phosphorylation at Ser-114 by GSK3-beta
CC       enhances ubiquitination by the DCX(DTL) complex. Phosphorylation
CC       of Thr-145 by PIM2 enhances CDKN1A stability and inhibits cell
CC       proliferation. Phosphorylation of Thr-145 by PIM1 results in the
CC       relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein
CC       stability. UV radiation-induced phosphorylation at Thr-80 by LKB1
CC       and at Ser-146 by NUAK1 leads to its degradation.
CC       {ECO:0000269|PubMed:10753973, ECO:0000269|PubMed:11463845,
CC       ECO:0000269|PubMed:12431783, ECO:0000269|PubMed:16982699,
CC       ECO:0000269|PubMed:18794347, ECO:0000269|PubMed:20307683,
CC       ECO:0000269|PubMed:25329316}.
CC   -!- PTM: Ubiquitinated by MKRN1; leading to polyubiquitination and 26S
CC       proteasome-dependent degradation. Ubiquitinated by the DCX(DTL)
CC       complex, also named CRL4(CDT2) complex, leading to its degradation
CC       during S phase or following UV irradiation. Ubiquitination by the
CC       DCX(DTL) complex is essential to control replication licensing and
CC       is PCNA-dependent: interacts with PCNA via its PIP-box, while the
CC       presence of the containing the 'K+4' motif in the PIP box, recruit
CC       the DCX(DTL) complex, leading to its degradation. Ubiquitination
CC       at Ser-2 leads to degradation by the proteasome pathway.
CC       Ubiquitinated by RNF114; leading to proteasomal degradation.
CC       {ECO:0000269|PubMed:15226418}.
CC   -!- PTM: Acetylation leads to protein stability. Acetylated in vitro
CC       on Lys-141, Lys-154, Lys-161 and Lys-163. Deacetylation by HDAC1
CC       is prevented by competitive binding of C10orf90/FATS to HDAC1 (By
CC       similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the CDI family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB59559.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=AAB59560.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CDKN1AID139.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cdkn1a/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L25610; AAA16109.1; -; mRNA.
DR   EMBL; S67388; AAB29246.1; -; mRNA.
DR   EMBL; U09579; AAA85641.1; -; mRNA.
DR   EMBL; U03106; AAC04313.1; -; mRNA.
DR   EMBL; L26165; AAA19811.1; -; mRNA.
DR   EMBL; L47232; AAB59559.1; ALT_INIT; mRNA.
DR   EMBL; L47233; AAB59560.1; ALT_INIT; mRNA.
DR   EMBL; AF497972; AAM11787.1; -; Genomic_DNA.
DR   EMBL; BT006719; AAP35365.1; -; mRNA.
DR   EMBL; AB451290; BAG70104.1; -; mRNA.
DR   EMBL; AB451422; BAG70236.1; -; mRNA.
DR   EMBL; CR536533; CAG38770.1; -; mRNA.
DR   EMBL; Z85996; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471081; EAX03904.1; -; Genomic_DNA.
DR   EMBL; BC000275; AAH00275.1; -; mRNA.
DR   EMBL; BC000312; AAH00312.1; -; mRNA.
DR   EMBL; BC001935; AAH01935.1; -; mRNA.
DR   EMBL; BC013967; AAH13967.1; -; mRNA.
DR   CCDS; CCDS4824.1; -.
DR   PIR; I54380; I54380.
DR   PIR; I68674; I68674.
DR   RefSeq; NP_000380.1; NM_000389.4.
DR   RefSeq; NP_001207706.1; NM_001220777.1.
DR   RefSeq; NP_001207707.1; NM_001220778.1.
DR   RefSeq; NP_001278478.1; NM_001291549.1.
DR   RefSeq; NP_510867.1; NM_078467.2.
DR   UniGene; Hs.370771; -.
DR   UniGene; Hs.732576; -.
DR   PDB; 1AXC; X-ray; 2.60 A; B/D/F=139-160.
DR   PDB; 2ZVV; X-ray; 2.00 A; X/Y=139-160.
DR   PDB; 2ZVW; X-ray; 2.50 A; I/J/K/L/M/N/O/P=139-160.
DR   PDB; 4RJF; X-ray; 2.01 A; B/D/F=139-160.
DR   PDB; 5E0U; X-ray; 1.93 A; D/E/F=139-160.
DR   PDBsum; 1AXC; -.
DR   PDBsum; 2ZVV; -.
DR   PDBsum; 2ZVW; -.
DR   PDBsum; 4RJF; -.
DR   PDBsum; 5E0U; -.
DR   DisProt; DP00016; -.
DR   ProteinModelPortal; P38936; -.
DR   SMR; P38936; -.
DR   BioGrid; 107460; 274.
DR   CORUM; P38936; -.
DR   DIP; DIP-246N; -.
DR   IntAct; P38936; 179.
DR   MINT; P38936; -.
DR   STRING; 9606.ENSP00000244741; -.
DR   BindingDB; P38936; -.
DR   ChEMBL; CHEMBL5021; -.
DR   iPTMnet; P38936; -.
DR   PhosphoSitePlus; P38936; -.
DR   BioMuta; CDKN1A; -.
DR   DMDM; 729143; -.
DR   SWISS-2DPAGE; P38936; -.
DR   EPD; P38936; -.
DR   PaxDb; P38936; -.
DR   PeptideAtlas; P38936; -.
DR   PRIDE; P38936; -.
DR   DNASU; 1026; -.
DR   Ensembl; ENST00000244741; ENSP00000244741; ENSG00000124762.
DR   Ensembl; ENST00000373711; ENSP00000362815; ENSG00000124762.
DR   Ensembl; ENST00000405375; ENSP00000384849; ENSG00000124762.
DR   Ensembl; ENST00000448526; ENSP00000409259; ENSG00000124762.
DR   Ensembl; ENST00000615513; ENSP00000482768; ENSG00000124762.
DR   GeneID; 1026; -.
DR   KEGG; hsa:1026; -.
DR   UCSC; uc003omm.5; human.
DR   CTD; 1026; -.
DR   DisGeNET; 1026; -.
DR   EuPathDB; HostDB:ENSG00000124762.13; -.
DR   GeneCards; CDKN1A; -.
DR   HGNC; HGNC:1784; CDKN1A.
DR   HPA; CAB000064; -.
DR   HPA; CAB069401; -.
DR   HPA; HPA005946; -.
DR   MalaCards; CDKN1A; -.
DR   MIM; 116899; gene.
DR   neXtProt; NX_P38936; -.
DR   OpenTargets; ENSG00000124762; -.
DR   Orphanet; 652; Multiple endocrine neoplasia type 1.
DR   PharmGKB; PA104; -.
DR   eggNOG; KOG4743; Eukaryota.
DR   eggNOG; ENOG410XXN5; LUCA.
DR   GeneTree; ENSGT00530000063588; -.
DR   HOGENOM; HOG000285999; -.
DR   HOVERGEN; HBG050868; -.
DR   InParanoid; P38936; -.
DR   KO; K06625; -.
DR   OMA; FAWERVW; -.
DR   OrthoDB; EOG091G19PZ; -.
DR   PhylomeDB; P38936; -.
DR   TreeFam; TF101038; -.
DR   Reactome; R-HSA-187577; SCF(Skp2)-mediated degradation of p27/p21.
DR   Reactome; R-HSA-198323; AKT phosphorylates targets in the cytosol.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence.
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
DR   Reactome; R-HSA-6804116; TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest.
DR   Reactome; R-HSA-68949; Orc1 removal from chromatin.
DR   Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition.
DR   Reactome; R-HSA-69231; Cyclin D associated events in G1.
DR   Reactome; R-HSA-69563; p53-Dependent G1 DNA Damage Response.
DR   Reactome; R-HSA-69656; Cyclin A:Cdk2-associated events at S phase entry.
DR   Reactome; R-HSA-69895; Transcriptional activation of cell cycle inhibitor p21.
DR   Reactome; R-HSA-8852276; The role of GTSE1 in G2/M progression after G2 checkpoint.
DR   Reactome; R-HSA-8866911; TFAP2 (AP-2) family regulates transcription of cell cycle factors.
DR   Reactome; R-HSA-8878166; Transcriptional regulation by RUNX2.
DR   Reactome; R-HSA-8941855; RUNX3 regulates CDKN1A transcription.
DR   SIGNOR; P38936; -.
DR   ChiTaRS; CDKN1A; human.
DR   EvolutionaryTrace; P38936; -.
DR   GeneWiki; P21; -.
DR   GenomeRNAi; 1026; -.
DR   PRO; PR:P38936; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000124762; -.
DR   CleanEx; HS_CDKN1A; -.
DR   ExpressionAtlas; P38936; baseline and differential.
DR   Genevisible; P38936; HS.
DR   GO; GO:0000307; C:cyclin-dependent protein kinase holoenzyme complex; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:MGI.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0070557; C:PCNA-p21 complex; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0032991; C:protein-containing complex; IDA:MGI.
DR   GO; GO:0030332; F:cyclin binding; IEA:Ensembl.
DR   GO; GO:0019912; F:cyclin-dependent protein kinase activating kinase activity; IDA:UniProtKB.
DR   GO; GO:0004693; F:cyclin-dependent protein serine/threonine kinase activity; EXP:Reactome.
DR   GO; GO:0004861; F:cyclin-dependent protein serine/threonine kinase inhibitor activity; TAS:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0019901; F:protein kinase binding; IPI:CAFA.
DR   GO; GO:0004860; F:protein kinase inhibitor activity; IMP:CAFA.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:CAFA.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:BHF-UCL.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; IMP:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IMP:BHF-UCL.
DR   GO; GO:0031668; P:cellular response to extracellular stimulus; IMP:BHF-UCL.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0034605; P:cellular response to heat; IEA:Ensembl.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IMP:BHF-UCL.
DR   GO; GO:0071493; P:cellular response to UV-B; ISS:UniProtKB.
DR   GO; GO:0090398; P:cellular senescence; IMP:BHF-UCL.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; IDA:BHF-UCL.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IEA:Ensembl.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IDA:BHF-UCL.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IMP:BHF-UCL.
DR   GO; GO:0060574; P:intestinal epithelial cell maturation; IEA:Ensembl.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:ProtInc.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0071850; P:mitotic cell cycle arrest; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:BHF-UCL.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:1904030; P:negative regulation of cyclin-dependent protein kinase activity; IMP:CAFA.
DR   GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IEA:Ensembl.
DR   GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IGI:MGI.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0042326; P:negative regulation of phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IEA:Ensembl.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IMP:BHF-UCL.
DR   GO; GO:0043068; P:positive regulation of programmed cell death; IEA:Ensembl.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IDA:MGI.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL.
DR   GO; GO:0043491; P:protein kinase B signaling; TAS:Reactome.
DR   GO; GO:0050821; P:protein stabilization; TAS:Reactome.
DR   GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL.
DR   GO; GO:0000079; P:regulation of cyclin-dependent protein serine/threonine kinase activity; TAS:ProtInc.
DR   GO; GO:2000278; P:regulation of DNA biosynthetic process; IEA:Ensembl.
DR   GO; GO:0033158; P:regulation of protein import into nucleus, translocation; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; TAS:Reactome.
DR   GO; GO:0090399; P:replicative senescence; IEA:Ensembl.
DR   GO; GO:0046685; P:response to arsenic-containing substance; IEA:Ensembl.
DR   GO; GO:0051412; P:response to corticosterone; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0055093; P:response to hyperoxia; IEA:Ensembl.
DR   GO; GO:0010243; P:response to organonitrogen compound; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0010165; P:response to X-ray; IEA:Ensembl.
DR   GO; GO:0090400; P:stress-induced premature senescence; TAS:BHF-UCL.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   InterPro; IPR003175; CDI.
DR   InterPro; IPR029841; CDKN1A_vertebrate.
DR   PANTHER; PTHR10265; PTHR10265; 1.
DR   PANTHER; PTHR10265:SF16; PTHR10265:SF16; 1.
DR   Pfam; PF02234; CDI; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cell cycle; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Metal-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Protein kinase inhibitor; Reference proteome;
KW   Ubl conjugation; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:15574338}.
FT   CHAIN         2    164       Cyclin-dependent kinase inhibitor 1.
FT                                /FTId=PRO_0000190079.
FT   ZN_FING      13     41       C4-type. {ECO:0000255}.
FT   REGION       17     24       Required for binding cyclins.
FT   REGION       53     58       Required for binding CDKs.
FT   MOTIF       140    164       PIP-box K+4 motif.
FT   MOTIF       141    156       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000269|PubMed:15574338}.
FT   MOD_RES      80     80       Phosphothreonine; by LKB1.
FT                                {ECO:0000269|PubMed:25329316}.
FT   MOD_RES     114    114       Phosphoserine; by GSK3-beta.
FT                                {ECO:0000269|PubMed:18794347}.
FT   MOD_RES     130    130       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648}.
FT   MOD_RES     145    145       Phosphothreonine; by PKA, PKB/AKT1, PIM1
FT                                and PIM2. {ECO:0000269|PubMed:10753973,
FT                                ECO:0000269|PubMed:11463845,
FT                                ECO:0000269|PubMed:12431783,
FT                                ECO:0000269|PubMed:16982699,
FT                                ECO:0000269|PubMed:20307683}.
FT   MOD_RES     146    146       Phosphoserine; by PKC and NUAK1.
FT                                {ECO:0000269|PubMed:10753973,
FT                                ECO:0000269|PubMed:25329316}.
FT   MOD_RES     160    160       Phosphoserine; by PKC; in vitro.
FT                                {ECO:0000269|PubMed:10753973}.
FT   CROSSLNK      2      2       Glycyl serine ester (Ser-Gly) (interchain
FT                                with G-Cter in ubiquitin).
FT                                {ECO:0000305|PubMed:15226418}.
FT   VARIANT       4      4       P -> L (in dbSNP:rs4986866).
FT                                /FTId=VAR_048686.
FT   VARIANT      31     31       S -> R (in dbSNP:rs1801270).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:7655464,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_011870.
FT   VARIANT      63     63       F -> L (in dbSNP:rs4986867).
FT                                /FTId=VAR_048687.
FT   MUTAGEN      80     80       T->A: Abolishes UV radiation-induced
FT                                phosphorylation and subsequent
FT                                degradation.
FT                                {ECO:0000269|PubMed:25329316}.
FT   MUTAGEN     114    114       S->E: Phosphomimetic mutant, increases
FT                                ubiquitination by the DCX(DTL) complex.
FT                                {ECO:0000269|PubMed:18794347}.
FT   MUTAGEN     144    150       QTSMTDF->ATSATDA: Abolishes interaction
FT                                with PCNA and subsequent degradation by
FT                                the proteasome.
FT                                {ECO:0000269|PubMed:18794347}.
FT   MUTAGEN     145    145       T->A: Reduces phosphorylation by Akt; no
FT                                change in interaction with PCNA, CDK2 or
FT                                CDK4; no change in subcellular location.
FT                                {ECO:0000269|PubMed:11463845}.
FT   MUTAGEN     145    145       T->D: No interaction with PCNA; 59%
FT                                inhibition of CDK2 binding; modest
FT                                inhibition of CDK4 binding; no change in
FT                                subcellular location.
FT                                {ECO:0000269|PubMed:11463845}.
FT   MUTAGEN     146    146       S->A: No change in interaction with PCNA.
FT                                Abolishes UV radiation-induced
FT                                phosphorylation and subsequent
FT                                degradation.
FT                                {ECO:0000269|PubMed:11463845,
FT                                ECO:0000269|PubMed:25329316}.
FT   MUTAGEN     146    146       S->D: Reduces interaction with PCNA.
FT                                {ECO:0000269|PubMed:11463845}.
FT   MUTAGEN     147    151       MTDFY->ATDAAA: Abolishes interaction with
FT                                PCNA and subsequent degradation by the
FT                                proteasome.
FT                                {ECO:0000269|PubMed:18703516}.
FT   MUTAGEN     154    156       KRR->AAA: Abolishes degradation by the
FT                                proteasome without affecting the
FT                                interaction with PCNA.
FT                                {ECO:0000269|PubMed:18703516}.
FT   HELIX       147    149       {ECO:0000244|PDB:5E0U}.
FT   STRAND      153    158       {ECO:0000244|PDB:5E0U}.
SQ   SEQUENCE   164 AA;  18119 MW;  98D1E7C519ADFCA9 CRC64;
     MSEPAGDVRQ NPCGSKACRR LFGPVDSEQL SRDCDALMAG CIQEARERWN FDFVTETPLE
     GDFAWERVRG LGLPKLYLPT GPRRGRDELG GGRRPGTSPA LLQGTAEEDH VDLSLSCTLV
     PRSGEQAEGS PGGPGDSQGR KRRQTSMTDF YHSKRRLIFS KRKP
//
ID   A0A024R9C1_HUMAN        Unreviewed;       636 AA.
AC   A0A024R9C1;
DT   09-JUL-2014, integrated into UniProtKB/TrEMBL.
DT   09-JUL-2014, sequence version 1.
DT   28-MAR-2018, entry version 37.
DE   RecName: Full=Polyadenylate-binding protein {ECO:0000256|RuleBase:RU362004};
DE            Short=PABP {ECO:0000256|RuleBase:RU362004};
GN   Name=PABPC1 {ECO:0000313|EMBL:EAW91817.1};
GN   ORFNames=hCG_15683 {ECO:0000313|EMBL:EAW91817.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAW91817.1};
RN   [1] {ECO:0000313|EMBL:EAW91817.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D.,
RA   Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q.,
RA   Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G.,
RA   Thomas P.D., Zhang J., Gabor Miklos G.L., Nelson C., Broder S.,
RA   Clark A.G., Nadeau J., McKusick V.A., Zinder N., Levine A.J.,
RA   Roberts R.J., Simon M., Slayman C., Hunkapiller M., Bolanos R.,
RA   Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A.,
RA   Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K.,
RA   Remington K., Abu-Threideh J., Beasley E., Biddick K., Bonazzi V.,
RA   Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z.,
RA   Guan P., Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A.,
RA   Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V.,
RA   Milshina N., Moore H.M., Naik A.K., Narayan V.A., Neelam B.,
RA   Nusskern D., Rusch D.B., Salzberg S., Shao W., Shue B., Sun J.,
RA   Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C.,
RA   Yao A., Ye J., Zhan M., Zhang W., Zhang H., Zhao Q., Zheng L.,
RA   Zhong F., Zhong W., Zhu S., Zhao S., Gilbert D., Baumhueter S.,
RA   Spier G., Carter C., Cravchik A., Woodage T., Ali F., An H., Awe A.,
RA   Baldwin D., Baden H., Barnstead M., Barrow I., Beeson K., Busam D.,
RA   Carver A., Center A., Cheng M.L., Curry L., Danaher S., Davenport L.,
RA   Desilets R., Dietz S., Dodson K., Doup L., Ferriera S., Garg N.,
RA   Gluecksmann A., Hart B., Haynes J., Haynes C., Heiner C., Hladun S.,
RA   Hostin D., Houck J., Howland T., Ibegwam C., Johnson J., Kalush F.,
RA   Kline L., Koduru S., Love A., Mann F., May D., McCawley S.,
RA   McIntosh T., McMullen I., Moy M., Moy L., Murphy B., Nelson K.,
RA   Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N.,
RA   Tse S., Vech C., Wang G., Wetter J., Williams S., Williams M.,
RA   Windsor S., Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F.,
RA   Guigo R., Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A.,
RA   Mi H., Lazareva B., Hatton T., Narechania A., Diemer K.,
RA   Muruganujan A., Guo N., Sato S., Bafna V., Istrail S., Lippert R.,
RA   Schwartz R., Walenz B., Yooseph S., Allen D., Basu A., Baxendale J.,
RA   Blick L., Caminha M., Carnes-Stine J., Caulk P., Chiang Y.H.,
RA   Coyne M., Dahlke C., Mays A., Dombroski M., Donnelly M., Ely D.,
RA   Esparham S., Fosler C., Gire H., Glanowski S., Glasser K., Glodek A.,
RA   Gorokhov M., Graham K., Gropman B., Harris M., Heil J., Henderson S.,
RA   Hoover J., Jennings D., Jordan C., Jordan J., Kasha J., Kagan L.,
RA   Kraft C., Levitsky A., Lewis M., Liu X., Lopez J., Ma D., Majoros W.,
RA   McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N., Nodell M.,
RA   Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAW91817.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Binds the poly(A) tail of mRNA.
CC       {ECO:0000256|RuleBase:RU362004}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU362004}.
CC   -!- SIMILARITY: Belongs to the polyadenylate-binding protein type-1
CC       family. {ECO:0000256|RuleBase:RU362004}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; CH471060; EAW91815.1; -; Genomic_DNA.
DR   EMBL; CH471060; EAW91817.1; -; Genomic_DNA.
DR   RefSeq; NP_002559.2; NM_002568.3.
DR   RefSeq; XP_005250918.1; XM_005250861.2.
DR   UniGene; Hs.387804; -.
DR   GeneID; 26986; -.
DR   KEGG; hsa:26986; -.
DR   CTD; 26986; -.
DR   EuPathDB; HostDB:ENSG00000070756.13; -.
DR   eggNOG; KOG0123; Eukaryota.
DR   eggNOG; ENOG410XR5X; LUCA.
DR   KO; K13126; -.
DR   OMA; RAAYYPA; -.
DR   OrthoDB; EOG091G03ZE; -.
DR   ChiTaRS; PABPC1; human.
DR   GenomeRNAi; 26986; -.
DR   Bgee; ENSG00000070756; -.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-UniRule.
DR   Gene3D; 3.30.70.330; -; 4.
DR   InterPro; IPR012677; Nucleotide-bd_a/b_plait_sf.
DR   InterPro; IPR036053; PABP-dom.
DR   InterPro; IPR006515; PABP_1234.
DR   InterPro; IPR002004; PABP_HYD.
DR   InterPro; IPR035979; RBD_domain_sf.
DR   InterPro; IPR000504; RRM_dom.
DR   InterPro; IPR003954; RRM_dom_euk.
DR   Pfam; PF00658; PABP; 1.
DR   Pfam; PF00076; RRM_1; 4.
DR   SMART; SM00517; PolyA; 1.
DR   SMART; SM00360; RRM; 4.
DR   SMART; SM00361; RRM_1; 3.
DR   SUPFAM; SSF54928; SSF54928; 2.
DR   SUPFAM; SSF63570; SSF63570; 1.
DR   TIGRFAMs; TIGR01628; PABP-1234; 1.
DR   PROSITE; PS51309; PABC; 1.
DR   PROSITE; PS50102; RRM; 4.
PE   3: Inferred from homology;
KW   Cytoplasm {ECO:0000256|RuleBase:RU362004};
KW   Repeat {ECO:0000256|SAAS:SAAS00454674};
KW   RNA-binding {ECO:0000256|PROSITE-ProRule:PRU00176,
KW   ECO:0000256|RuleBase:RU362004, ECO:0000256|SAAS:SAAS00572889}.
FT   DOMAIN       11     89       RRM. {ECO:0000259|PROSITE:PS50102}.
FT   DOMAIN       99    175       RRM. {ECO:0000259|PROSITE:PS50102}.
FT   DOMAIN      191    268       RRM. {ECO:0000259|PROSITE:PS50102}.
FT   DOMAIN      294    370       RRM. {ECO:0000259|PROSITE:PS50102}.
FT   DOMAIN      542    619       PABC. {ECO:0000259|PROSITE:PS51309}.
SQ   SEQUENCE   636 AA;  70671 MW;  2EB1B02A346132EE CRC64;
     MNPSAPSYPM ASLYVGDLHP DVTEAMLYEK FSPAGPILSI RVCRDMITRR SLGYAYVNFQ
     QPADAERALD TMNFDVIKGK PVRIMWSQRD PSLRKSGVGN IFIKNLDKSI DNKALYDTFS
     AFGNILSCKV VCDENGSKGY GFVHFETQEA AERAIEKMNG MLLNDRKVFV GRFKSRKERE
     AELGARAKEF TNVYIKNFGE DMDDERLKDL FGKFGPALSV KVMTDESGKS KGFGFVSFER
     HEDAQKAVDE MNGKELNGKQ IYVGRAQKKV ERQTELKRKF EQMKQDRITR YQGVNLYVKN
     LDDGIDDERL RKEFSPFGTI TSAKVMMEGG RSKGFGFVCF SSPEEATKAV TEMNGRIVAT
     KPLYVALAQR KEERQAHLTN QYMQRMASVR AVPNPVINPY QPAPPSGYFM AAIPQTQNRA
     AYYPPSQIAQ LRPSPRWTAQ GARPHPFQNM PGAIRPAAPR PPFSTMRPAS SQVPRVMSTQ
     RVANTSTQTM GPRPAAAAAA ATPAVRTVPQ YKYAAGVRNP QQHLNAQPQV TMQQPAVHVQ
     GQEPLTASML ASAPPQEQKQ MLGERLFPLI QAMHPTLAGK ITGMLLEIDN SELLHMLESP
     ESLRSKVDEA VAVLQAHQAK EAAQKAVNSA TGVPTV
//
ID   PABP1_HUMAN             Reviewed;         636 AA.
AC   P11940; Q15097; Q93004;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   25-APR-2018, entry version 223.
DE   RecName: Full=Polyadenylate-binding protein 1;
DE            Short=PABP-1;
DE            Short=Poly(A)-binding protein 1;
GN   Name=PABPC1; Synonyms=PAB1, PABP1, PABPC2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2885805; DOI=10.1093/nar/15.12.4771;
RA   Grange T., de Sa C.M., Oddos J., Pictet R.;
RT   "Human mRNA polyadenylate binding protein: evolutionary conservation
RT   of a nucleic acid binding motif.";
RL   Nucleic Acids Res. 15:4771-4787(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Lung;
RA   Hornstein E., Abramzon-Talianker A., Wiesel I., Meyuhas O.;
RT   "The human poly(A)-binding protein (PABP) gene: structural and
RT   functional analysis.";
RL   Submitted (SEP-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 26-636 (ISOFORM 2).
RA   Murphy E.P., McKenna N.J., Headon D.R.;
RT   "Nucleotide sequence of a partial cDNA encoding a novel human
RT   polyadenylate-binding protein.";
RL   Submitted (FEB-1995) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   PROTEIN SEQUENCE OF 31-41; 51-78; 84-89; 96-104; 158-166; 189-196;
RP   214-221; 232-240; 291-309; 312-324; 357-370; 375-385; 482-506; 566-580
RP   AND 605-620, METHYLATION AT ARG-493, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Colon carcinoma, and Ovarian carcinoma;
RA   Bienvenut W.V., Zebisch A., Lilla S., von Kriegsheim A., Lempens A.,
RA   Kolch W.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [7]
RP   PROTEIN SEQUENCE OF 31-41; 51-78; 84-89; 96-104; 114-129; 139-153;
RP   158-166; 187-208; 214-221; 232-240; 291-324; 334-348; 357-370;
RP   375-385; 482-506; 519-559; 566-620 AND 626-636, METHYLATION AT LYS-299
RP   AND ARG-493, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RA   Bienvenut W.V., Waridel P., Quadroni M.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [8]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA], AND SUBCELLULAR LOCATION.
RX   PubMed=7908267; DOI=10.1006/excr.1994.1104;
RA   Goerlach M., Burd C.G., Dreyfuss G.;
RT   "The mRNA poly(A)-binding protein: localization, abundance, and RNA-
RT   binding specificity.";
RL   Exp. Cell Res. 211:400-407(1994).
RN   [9]
RP   SUBCELLULAR LOCATION.
RX   PubMed=9582337; DOI=10.1074/jbc.273.21.13015;
RA   Afonina E., Stauber R., Pavlakis G.N.;
RT   "The human poly(A)-binding protein 1 shuttles between the nucleus and
RT   the cytoplasm.";
RL   J. Biol. Chem. 273:13015-13021(1998).
RN   [10]
RP   INTERACTION WITH PAIP1, AND DOMAIN.
RX   PubMed=9548260; DOI=10.1038/33198;
RA   Craig A.W.B., Haghighat A., Yu A.T.K., Sonenberg N.;
RT   "Interaction of polyadenylate-binding protein with the eIF4G homologue
RT   PAIP enhances translation.";
RL   Nature 392:520-523(1998).
RN   [11]
RP   FUNCTION IN TRANSLATIONALLY COUPLED MRNA TURNOVER, AND IDENTIFICATION
RP   IN A COMPLEX WITH HNRPD; SYNCRIP; PAIP1 AND CSDE1.
RX   PubMed=11051545; DOI=10.1016/S0092-8674(00)00102-1;
RA   Grosset C., Chen C.-Y.A., Xu N., Sonenberg N., Jacquemin-Sablon H.,
RA   Shyu A.-B.;
RT   "A mechanism for translationally coupled mRNA turnover: interaction
RT   between the poly(A) tail and a c-fos RNA coding determinant via a
RT   protein complex.";
RL   Cell 103:29-40(2000).
RN   [12]
RP   INTERACTION WITH PAIP2.
RX   PubMed=11172725; DOI=10.1016/S1097-2765(01)00168-X;
RA   Khaleghpour K., Svitkin Y.V., Craig A.W.B., DeMaria C.T., Deo R.C.,
RA   Burley S.K., Sonenberg N.;
RT   "Translational repression by a novel partner of human poly(A) binding
RT   protein, Paip2.";
RL   Mol. Cell 7:205-216(2001).
RN   [13]
RP   INTERACTION WITH PAIP2.
RX   PubMed=11438674; DOI=10.1128/MCB.21.15.5200-5213.2001;
RA   Khaleghpour K., Kahvejian A., De Crescenzo G., Roy G., Svitkin Y.V.,
RA   Imataka H., O'Connor-McCourt M., Sonenberg N.;
RT   "Dual interactions of the translational repressor Paip2 with poly(A)
RT   binding protein.";
RL   Mol. Cell. Biol. 21:5200-5213(2001).
RN   [14]
RP   METHYLATION AT ARG-455 AND ARG-460, AND MUTAGENESIS OF ARG-455 AND
RP   ARG-460.
RX   PubMed=11850402; DOI=10.1093/embo-reports/kvf052;
RA   Lee J., Bedford M.T.;
RT   "PABP1 identified as an arginine methyltransferase substrate using
RT   high-density protein arrays.";
RL   EMBO Rep. 3:268-273(2002).
RN   [15]
RP   INTERACTION WITH PAIP1.
RX   PubMed=11997512; DOI=10.1128/MCB.22.11.3769-3782.2002;
RA   Roy G., De Crescenzo G., Khaleghpour K., Kahvejian A.,
RA   O'Connor-McCourt M., Sonenberg N.;
RT   "Paip1 interacts with poly(A) binding protein through two independent
RT   binding motifs.";
RL   Mol. Cell. Biol. 22:3769-3782(2002).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE
RP   SPLICEOSOMAL C COMPLEX.
RX   PubMed=11991638; DOI=10.1017/S1355838202021088;
RA   Jurica M.S., Licklider L.J., Gygi S.P., Grigorieff N., Moore M.J.;
RT   "Purification and characterization of native spliceosomes suitable for
RT   three-dimensional structural analysis.";
RL   RNA 8:426-439(2002).
RN   [17]
RP   PHOSPHORYLATION BY MAPKAPK2.
RX   PubMed=12565831; DOI=10.1016/S0006-291X(03)00015-9;
RA   Bollig F., Winzen R., Gaestel M., Kostka S., Resch K., Holtmann H.;
RT   "Affinity purification of ARE-binding proteins identifies polyA-
RT   binding protein 1 as a potential substrate in MK2-induced mRNA
RT   stabilization.";
RL   Biochem. Biophys. Res. Commun. 301:665-670(2003).
RN   [18]
RP   INTERACTION WITH CSDE1.
RX   PubMed=15314026; DOI=10.1101/gad.1219104;
RA   Chang T.-C., Yamashita A., Chen C.-Y.A., Yamashita Y., Zhu W.,
RA   Durdan S., Kahvejian A., Sonenberg N., Shyu A.-B.;
RT   "UNR, a new partner of poly(A)-binding protein, plays a key role in
RT   translationally coupled mRNA turnover mediated by the c-fos major
RT   coding-region determinant.";
RL   Genes Dev. 18:2010-2023(2004).
RN   [19]
RP   IDENTIFICATION IN A MRNP COMPLEX WITH IGF2BP1 AND CSDE1.
RX   PubMed=16356927; DOI=10.1093/nar/gki1014;
RA   Patel G.P., Ma S., Bag J.;
RT   "The autoregulatory translational control element of poly(A)-binding
RT   protein mRNA forms a heteromeric ribonucleoprotein complex.";
RL   Nucleic Acids Res. 33:7074-7089(2005).
RN   [20]
RP   FUNCTION, HOMODIMERIZATION, INTERACTION WITH IGF2BP1, AND RNA-BINDING.
RX   PubMed=17212783; DOI=10.1111/j.1742-4658.2006.05556.x;
RA   Patel G.P., Bag J.;
RT   "IMP1 interacts with poly(A)-binding protein (PABP) and the
RT   autoregulatory translational control element of PABP-mRNA through the
RT   KH III-IV domain.";
RL   FEBS J. 273:5678-5690(2006).
RN   [21]
RP   INTERACTION WITH PAIP2B.
RX   PubMed=16804161; DOI=10.1261/rna.106506;
RA   Berlanga J.J., Baass A., Sonenberg N.;
RT   "Regulation of poly(A) binding protein function in translation:
RT   Characterization of the Paip2 homolog, Paip2B.";
RL   RNA 12:1556-1568(2006).
RN   [22]
RP   INTERACTION WITH AGO1 AND AGO2.
RX   PubMed=17932509; DOI=10.1038/sj.embor.7401088;
RA   Hoeck J., Weinmann L., Ender C., Ruedel S., Kremmer E., Raabe M.,
RA   Urlaub H., Meister G.;
RT   "Proteomic and functional analysis of Argonaute-containing mRNA-
RT   protein complexes in human cells.";
RL   EMBO Rep. 8:1052-1060(2007).
RN   [23]
RP   INTERACTION WITH NFX1.
RX   PubMed=17267499; DOI=10.1128/JVI.02007-06;
RA   Katzenellenbogen R.A., Egelkrout E.M., Vliet-Gregg P., Gewin L.C.,
RA   Gafken P.R., Galloway D.A.;
RT   "NFX1-123 and poly(A) binding proteins synergistically augment
RT   activation of telomerase in human papillomavirus type 16 E6-expressing
RT   cells.";
RL   J. Virol. 81:3786-3796(2007).
RN   [24]
RP   IDENTIFICATION IN A MRNP GRANULE COMPLEX, INTERACTION WITH IGF2BP1,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=17289661; DOI=10.1074/mcp.M600346-MCP200;
RA   Joeson L., Vikesaa J., Krogh A., Nielsen L.K., Hansen T., Borup R.,
RA   Johnsen A.H., Christiansen J., Nielsen F.C.;
RT   "Molecular composition of IMP1 ribonucleoprotein granules.";
RL   Mol. Cell. Proteomics 6:798-811(2007).
RN   [25]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18799579; DOI=10.1128/JVI.00872-08;
RA   Harb M., Becker M.M., Vitour D., Baron C.H., Vende P., Brown S.C.,
RA   Bolte S., Arold S.T., Poncet D.;
RT   "Nuclear localization of cytoplasmic poly(A)-binding protein upon
RT   rotavirus infection involves the interaction of NSP3 with eIF4G and
RT   RoXaN.";
RL   J. Virol. 82:11283-11293(2008).
RN   [26]
RP   FUNCTION IN NONSENSE-MEDIATED MRNA DECAY, AND INTERACTION WITH GSPT2.
RX   PubMed=18447585; DOI=10.1371/journal.pbio.0060111;
RA   Singh G., Rebbapragada I., Lykke-Andersen J.;
RT   "A competition between stimulators and antagonists of Upf complex
RT   recruitment governs human nonsense-mediated mRNA decay.";
RL   PLoS Biol. 6:E111-E111(2008).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [28]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [29]
RP   IDENTIFICATION IN A MRNP COMPLEX, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=19029303; DOI=10.1261/rna.1175909;
RA   Weidensdorfer D., Stoehr N., Baude A., Lederer M., Koehn M.,
RA   Schierhorn A., Buchmeier S., Wahle E., Huettelmaiery S.;
RT   "Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic
RT   RNPs.";
RL   RNA 15:104-115(2009).
RN   [30]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-512, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [31]
RP   REVIEW.
RX   PubMed=20102337; DOI=10.1042/BJ20091571;
RA   Smith R.W., Gray N.K.;
RT   "Poly(A)-binding protein (PABP): a common viral target.";
RL   Biochem. J. 426:1-12(2010).
RN   [32]
RP   INTERACTION WITH LARP1.
RX   PubMed=20430826; DOI=10.1093/nar/gkq294;
RA   Burrows C., Abd Latip N., Lam S.J., Carpenter L., Sawicka K.,
RA   Tzolovsky G., Gabra H., Bushell M., Glover D.M., Willis A.E.,
RA   Blagden S.P.;
RT   "The RNA binding protein Larp1 regulates cell division, apoptosis and
RT   cell migration.";
RL   Nucleic Acids Res. 38:5542-5553(2010).
RN   [33]
RP   INTERACTION WITH HHV-5 PROTEIN UL69.
RX   PubMed=20133758; DOI=10.1073/pnas.0914856107;
RA   Aoyagi M., Gaspar M., Shenk T.E.;
RT   "Human cytomegalovirus UL69 protein facilitates translation by
RT   associating with the mRNA cap-binding complex and excluding 4EBP1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:2640-2645(2010).
RN   [34]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PABPC1 AND RACK1.
RX   PubMed=20573744; DOI=10.1261/rna.2146910;
RA   Schaffler K., Schulz K., Hirmer A., Wiesner J., Grimm M., Sickmann A.,
RA   Fischer U.;
RT   "A stimulatory role for the La-related protein 4B in translation.";
RL   RNA 16:1488-1499(2010).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [37]
RP   INTERACTION WITH SETX.
RX   PubMed=21700224; DOI=10.1016/j.molcel.2011.04.026;
RA   Skourti-Stathaki K., Proudfoot N.J., Gromak N.;
RT   "Human senataxin resolves RNA/DNA hybrids formed at transcriptional
RT   pause sites to promote Xrn2-dependent termination.";
RL   Mol. Cell 42:794-805(2011).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315 AND THR-319, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [39]
RP   INTERACTION WITH TRIM71.
RX   PubMed=23125361; DOI=10.1093/nar/gks1032;
RA   Loedige I., Gaidatzis D., Sack R., Meister G., Filipowicz W.;
RT   "The mammalian TRIM-NHL protein TRIM71/LIN-41 is a repressor of mRNA
RT   function.";
RL   Nucleic Acids Res. 41:518-532(2013).
RN   [40]
RP   FUNCTION.
RX   PubMed=25480299; DOI=10.1016/j.cell.2014.10.055;
RA   Lim J., Ha M., Chang H., Kwon S.C., Simanshu D.K., Patel D.J.,
RA   Kim V.N.;
RT   "Uridylation by TUT4 and TUT7 marks mRNA for degradation.";
RL   Cell 159:1365-1376(2014).
RN   [41]
RP   INTERACTION WITH LARP1.
RX   PubMed=24532714; DOI=10.1101/gad.231407.113;
RA   Tcherkezian J., Cargnello M., Romeo Y., Huttlin E.L., Lavoie G.,
RA   Gygi S.P., Roux P.P.;
RT   "Proteomic analysis of cap-dependent translation identifies LARP1 as a
RT   key regulator of 5'TOP mRNA translation.";
RL   Genes Dev. 28:357-371(2014).
RN   [42]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-385; ARG-419; ARG-432;
RP   ARG-436; ARG-481; ARG-493; ARG-506 AND ARG-518, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [43]
RP   INTERACTION WITH LARP1.
RX   PubMed=25940091; DOI=10.1074/jbc.M114.621730;
RA   Fonseca B.D., Zakaria C., Jia J.J., Graber T.E., Svitkin Y.,
RA   Tahmasebi S., Healy D., Hoang H.D., Jensen J.M., Diao I.T.,
RA   Lussier A., Dajadian C., Padmanabhan N., Wang W., Matta-Camacho E.,
RA   Hearnden J., Smith E.M., Tsukumo Y., Yanagiya A., Morita M.,
RA   Petroulakis E., Gonzalez J.L., Hernandez G., Alain T., Damgaard C.K.;
RT   "La-related protein 1 (LARP1) represses terminal oligopyrimidine (TOP)
RT   mRNA translation downstream of mTOR complex 1 (mTORC1).";
RL   J. Biol. Chem. 290:15996-16020(2015).
RN   [44]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [45]
RP   INTERACTION WITH ZFC3H1.
RX   PubMed=27871484; DOI=10.1016/j.molcel.2016.09.025;
RA   Meola N., Domanski M., Karadoulama E., Chen Y., Gentil C., Pultz D.,
RA   Vitting-Seerup K., Lykke-Andersen S., Andersen J.S., Sandelin A.,
RA   Jensen T.H.;
RT   "Identification of a nuclear exosome decay pathway for processed
RT   transcripts.";
RL   Mol. Cell 64:520-533(2016).
RN   [46]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, INTERACTION WITH RYDEN,
RP   AND IDENTIFICATION IN A COMPLEX WITH RYDEN AND LARP1.
RX   PubMed=26735137; DOI=10.1371/journal.ppat.1005357;
RA   Suzuki Y., Chin W.X., Han Q., Ichiyama K., Lee C.H., Eyo Z.W.,
RA   Ebina H., Takahashi H., Takahashi C., Tan B.H., Hishiki T., Ohba K.,
RA   Matsuyama T., Koyanagi Y., Tan Y.J., Sawasaki T., Chu J.J.,
RA   Vasudevan S.G., Sano K., Yamamoto N.;
RT   "Characterization of RyDEN (C19orf66) as an interferon-stimulated
RT   cellular inhibitor against dengue virus replication.";
RL   PLoS Pathog. 12:E1005357-E1005357(2016).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 1-190.
RX   PubMed=10499800; DOI=10.1016/S0092-8674(00)81517-2;
RA   Deo R.C., Bonanno J.B., Sonenberg N., Burley S.K.;
RT   "Recognition of polyadenylate RNA by the poly(A)-binding protein.";
RL   Cell 98:835-845(1999).
RN   [48]
RP   STRUCTURE BY NMR OF 498-636, INTERACTION WITH GSPT1; PAIP1 AND PAIP2,
RP   AND DOMAIN.
RX   PubMed=11287632; DOI=10.1073/pnas.071024998;
RA   Kozlov G., Trempe J.F., Khaleghpour K., Kahvejian A., Ekiel I.,
RA   Gehring K.;
RT   "Structure and function of the C-terminal PABC domain of human
RT   poly(A)-binding protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:4409-4413(2001).
RN   [49]
RP   STRUCTURE BY NMR OF 541-623 IN COMPLEX WITH GSPT1.
RA   Osawa M., Nakanishi T., Hosoda N., Uchida S., Hoshino T., Katada I.,
RA   Shimada I.;
RT   "Eukaryotic translation termination factor Gspt/ERF3 recognizes Pabp
RT   with chemical exchange using two overlapping motifs.";
RL   Submitted (MAY-2009) to the PDB data bank.
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 544-626 IN COMPLEX WITH
RP   PAIP2, AND DOMAIN.
RX   PubMed=20096703; DOI=10.1016/j.jmb.2010.01.032;
RA   Kozlov G., Menade M., Rosenauer A., Nguyen L., Gehring K.;
RT   "Molecular determinants of PAM2 recognition by the MLLE domain of
RT   poly(A)-binding protein.";
RL   J. Mol. Biol. 397:397-407(2010).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 543-621 IN COMPLEX WITH
RP   LARP4B.
RA   Grimm C., Pelz J.P.;
RT   "LARP4B binds to the PABC1 MLLE domain via a variant PAM2 motif.";
RL   Submitted (DEC-2010) to the PDB data bank.
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 544-626 IN COMPLEX WITH
RP   LARP4.
RX   PubMed=21098120; DOI=10.1128/MCB.01162-10;
RA   Yang R., Gaidamakov S.A., Xie J., Lee J., Martino L., Kozlov G.,
RA   Crawford A.K., Russo A.N., Conte M.R., Gehring K., Maraia R.J.;
RT   "La-related protein 4 binds poly(A), interacts with the poly(A)-
RT   binding protein MLLE domain via a variant PAM2w motif, and can promote
RT   mRNA stability.";
RL   Mol. Cell. Biol. 31:542-556(2011).
CC   -!- FUNCTION: Binds the poly(A) tail of mRNA, including that of its
CC       own transcript. May be involved in cytoplasmic regulatory
CC       processes of mRNA metabolism such as pre-mRNA splicing. Its
CC       function in translational initiation regulation can either be
CC       enhanced by PAIP1 or repressed by PAIP2. Can probably bind to
CC       cytoplasmic RNA sequences other than poly(A) in vivo. Involved in
CC       translationally coupled mRNA turnover. Implicated with other RNA-
CC       binding proteins in the cytoplasmic deadenylation/translational
CC       and decay interplay of the FOS mRNA mediated by the major coding-
CC       region determinant of instability (mCRD) domain. Involved in
CC       regulation of nonsense-mediated decay (NMD) of mRNAs containing
CC       premature stop codons; for the recognition of premature
CC       termination codons (PTC) and initiation of NMD a competitive
CC       interaction between UPF1 and PABPC1 with the ribosome-bound
CC       release factors is proposed. By binding to long poly(A) tails, may
CC       protect them from uridylation by ZCCHC6/ZCCHC11 and hence
CC       contribute to mRNA stability (PubMed:25480299). Positively
CC       regulates the replication of dengue virus (DENV)
CC       (PubMed:26735137). {ECO:0000269|PubMed:11051545,
CC       ECO:0000269|PubMed:17212783, ECO:0000269|PubMed:18447585,
CC       ECO:0000269|PubMed:20573744, ECO:0000269|PubMed:25480299,
CC       ECO:0000269|PubMed:26735137}.
CC   -!- SUBUNIT: May interact with SETX (PubMed:21700224). May form
CC       homodimers. Component of a multisubunit autoregulatory
CC       ribonucleoprotein complex (ARC), at least composed of IGF2BP1,
CC       PABPC1 and CSDE1 (PubMed:16356927). Directly interacts with
CC       IGF2BP1. Part of a complex associated with the FOS mCRD domain and
CC       consisting of HNRPD, SYNCRIP, PAIP1 and CSDE1/UNR
CC       (PubMed:11051545). Interacts with the PABPC1-interacting motif-1
CC       (PAM1) and -2 (PAM2) of PAIP1 and PAIP2 (PubMed:9548260,
CC       PubMed:11172725, PubMed:11438674, PubMed:11997512,
CC       PubMed:11287632, PubMed:20096703). Interacts with PAIP1 with a 1:1
CC       stoichiometry and with PAIP2 with a 1:2 stoichiometry. The
CC       interaction with CSDE1 is direct and RNA-independent. Found in a
CC       mRNP complex with YBX2 (By similarity). Interacts with PAPD4/GLD2
CC       (By similarity). Identified in the spliceosome C complex
CC       (PubMed:11991638). Identified in a mRNP complex, at least composed
CC       of DHX9, DDX3X, ELAVL1, HNRNPU, IGF2BP1, ILF3, PABPC1, PCBP2,
CC       PTBP2, STAU1, STAU2, SYNCRIP and YBX1. Identified in a IGF2BP1-
CC       dependent mRNP granule complex containing untranslated mRNAs.
CC       Interacts with NFX1 (PubMed:17267499). Interacts with PIWIL1 (By
CC       similarity). Interacts with AGO1, AGO2, GSPT1 and GSPT2
CC       (PubMed:17932509, PubMed:18447585, Ref.49). Interacts with human
CC       cytomegalovirus/HHV-5 protein UL69 (PubMed:20133758). Interacts
CC       with LARP4B (Ref.51). Interacts (via the second and third RRM
CC       domains and the C-terminus) with PAIP2B (via central acidic
CC       portion and C-terminus) (PubMed:16804161, PubMed:11287632).
CC       Interacts with LARP1 (PubMed:20430826, PubMed:24532714,
CC       PubMed:25940091). Interacts with RYDEN (PubMed:26735137). Found in
CC       a complex with RYDEN and LARP1 (PubMed:26735137). Interacts with
CC       LARP4 (PubMed:21098120). Interacts with ZFC3H1 in a RNase-
CC       sensitive manner (PubMed:27871484). Interacts with TRIM71 (via NHL
CC       repeats) in an RNA-dependent manner (PubMed:23125361).
CC       {ECO:0000250|UniProtKB:P29341, ECO:0000269|PubMed:11051545,
CC       ECO:0000269|PubMed:11172725, ECO:0000269|PubMed:11287632,
CC       ECO:0000269|PubMed:11438674, ECO:0000269|PubMed:11991638,
CC       ECO:0000269|PubMed:11997512, ECO:0000269|PubMed:15314026,
CC       ECO:0000269|PubMed:16356927, ECO:0000269|PubMed:16804161,
CC       ECO:0000269|PubMed:17212783, ECO:0000269|PubMed:17267499,
CC       ECO:0000269|PubMed:17289661, ECO:0000269|PubMed:17932509,
CC       ECO:0000269|PubMed:18447585, ECO:0000269|PubMed:19029303,
CC       ECO:0000269|PubMed:20096703, ECO:0000269|PubMed:20133758,
CC       ECO:0000269|PubMed:20430826, ECO:0000269|PubMed:20573744,
CC       ECO:0000269|PubMed:21098120, ECO:0000269|PubMed:21700224,
CC       ECO:0000269|PubMed:23125361, ECO:0000269|PubMed:24532714,
CC       ECO:0000269|PubMed:26735137, ECO:0000269|PubMed:27871484,
CC       ECO:0000269|PubMed:9548260, ECO:0000269|Ref.49}.
CC   -!- INTERACTION:
CC       Q99700:ATXN2; NbExp=6; IntAct=EBI-81531, EBI-697691;
CC       O00571:DDX3X; NbExp=10; IntAct=EBI-81531, EBI-353779;
CC       P06730:EIF4E; NbExp=5; IntAct=EBI-81531, EBI-73440;
CC       Q04637:EIF4G1; NbExp=6; IntAct=EBI-81531, EBI-73711;
CC       O43432:EIF4G3; NbExp=2; IntAct=EBI-81531, EBI-464766;
CC       P15170-2:GSPT1; NbExp=2; IntAct=EBI-81531, EBI-9094806;
CC       Q8IYD1:GSPT2; NbExp=7; IntAct=EBI-81531, EBI-3869637;
CC       Q14103-4:HNRNPD; NbExp=2; IntAct=EBI-81531, EBI-432545;
CC       P35568:IRS1; NbExp=2; IntAct=EBI-81531, EBI-517592;
CC       Q09161:NCBP1; NbExp=4; IntAct=EBI-81531, EBI-464743;
CC       Q86U42:PABPN1; NbExp=2; IntAct=EBI-81531, EBI-1226435;
CC       Q9H074:PAIP1; NbExp=17; IntAct=EBI-81531, EBI-81519;
CC       Q9BPZ3:PAIP2; NbExp=5; IntAct=EBI-81531, EBI-2957445;
CC       Q58A45:PAN3; NbExp=4; IntAct=EBI-81531, EBI-2513054;
CC       Q15365:PCBP1; NbExp=2; IntAct=EBI-81531, EBI-946095;
CC       Q15366:PCBP2; NbExp=2; IntAct=EBI-81531, EBI-945799;
CC       Q96Q15:SMG1; NbExp=2; IntAct=EBI-81531, EBI-1049832;
CC       Q8NDV7:TNRC6A; NbExp=3; IntAct=EBI-81531, EBI-2269715;
CC       Q9UPQ9:TNRC6B; NbExp=3; IntAct=EBI-81531, EBI-947158;
CC       Q9HCJ0:TNRC6C; NbExp=22; IntAct=EBI-81531, EBI-6507625;
CC       P50616:TOB1; NbExp=4; IntAct=EBI-81531, EBI-723281;
CC       Q14106:TOB2; NbExp=4; IntAct=EBI-81531, EBI-2562000;
CC       Q9J0X9:UL54 (xeno); NbExp=3; IntAct=EBI-81531, EBI-7967856;
CC       P61981:YWHAG; NbExp=2; IntAct=EBI-81531, EBI-359832;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:20573744,
CC       ECO:0000269|PubMed:7908267, ECO:0000269|PubMed:9582337}. Nucleus
CC       {ECO:0000269|PubMed:18799579, ECO:0000269|PubMed:9582337}.
CC       Note=Localized in cytoplasmic mRNP granules containing
CC       untranslated mRNAs (PubMed:17289661). Shuttles between the
CC       cytoplasm and the nucleus (PubMed:9582337).
CC       {ECO:0000269|PubMed:17289661, ECO:0000269|PubMed:9582337}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P11940-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P11940-2; Sequence=VSP_009846;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- DOMAIN: The RNA-binding domains RRM1 and RRM2 and the C-terminus
CC       (last 138 amino acids) regions interact with the PABPC1-
CC       interacting motif-1 (PAM1) and -2 (PAM2) of PAIP1, respectively.
CC       {ECO:0000269|PubMed:11287632, ECO:0000269|PubMed:11997512}.
CC   -!- DOMAIN: The RNA-binding domains RRM2 and RRM3 and the C-terminus
CC       (last 138 amino acids) regions interact with the PABPC1-
CC       interacting motif-1 (PAM1) and -2 (PAM2) of PAIP2, respectively.
CC       {ECO:0000269|PubMed:11287632, ECO:0000269|PubMed:20096703}.
CC   -!- PTM: Phosphorylated by MAPKAPK2. {ECO:0000269|PubMed:12565831}.
CC   -!- PTM: Methylated by CARM1. Arg-493 is dimethylated, probably to
CC       asymmetric dimethylarginine. {ECO:0000269|PubMed:11850402,
CC       ECO:0000269|Ref.6, ECO:0000269|Ref.7}.
CC   -!- MISCELLANEOUS: Many viruses shutoff host mRNA translational
CC       machinery by inhibiting cellular PABPC1 activity using different
CC       mechanisms. Picornaviruses, caliciviruses or lentiviruses encode
CC       proteases that cleave PABPC1 at several defined sites in the
CC       proline-rich linker region between RRMs and the C-terminal domain.
CC       Rotaviruses, gammherpesviruses and bunyamwera virus relocalize
CC       PABPC1 from the cytoplasm to the nucleus thus altering its
CC       function. Many of these viruses translate their mRNA in a PABPC1-
CC       independent manner and are unaffected by host PABPC1 inhibition.
CC   -!- SIMILARITY: Belongs to the polyadenylate-binding protein type-1
CC       family. {ECO:0000305}.
CC   -!- CAUTION: Was termed (Ref.5) polyadenylate binding protein II.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y00345; CAA68428.1; -; mRNA.
DR   EMBL; U68104; AAD08718.1; -; Genomic_DNA.
DR   EMBL; U68093; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; U68094; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; U68095; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; U68097; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; U68098; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; U68099; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; U68100; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; U68101; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; U68102; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; U68103; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; AP001205; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015958; AAH15958.1; -; mRNA.
DR   EMBL; BC023520; AAH23520.1; -; mRNA.
DR   EMBL; Z48501; CAA88401.1; -; mRNA.
DR   CCDS; CCDS6289.1; -. [P11940-1]
DR   PIR; A93668; DNHUPA.
DR   PIR; S52491; S52491.
DR   RefSeq; NP_002559.2; NM_002568.3. [P11940-1]
DR   RefSeq; XP_005250918.1; XM_005250861.2. [P11940-1]
DR   UniGene; Hs.387804; -.
DR   PDB; 1CVJ; X-ray; 2.60 A; A/B/C/D/E/F/G/H=1-190.
DR   PDB; 1G9L; NMR; -; A=498-636.
DR   PDB; 1JGN; NMR; -; A=544-636.
DR   PDB; 1JH4; NMR; -; A=544-636.
DR   PDB; 2K8G; NMR; -; A=90-182.
DR   PDB; 2RQG; NMR; -; B=541-623.
DR   PDB; 2RQH; NMR; -; B=541-623.
DR   PDB; 2X04; X-ray; 1.49 A; A/B=545-619.
DR   PDB; 3KTP; X-ray; 1.50 A; A=544-626.
DR   PDB; 3KTR; X-ray; 1.70 A; A=544-626.
DR   PDB; 3KUI; X-ray; 2.30 A; A=544-626.
DR   PDB; 3KUJ; X-ray; 1.40 A; A=544-626.
DR   PDB; 3KUR; X-ray; 2.50 A; A/B/C/D/E/F/G/H=544-617.
DR   PDB; 3KUS; X-ray; 1.40 A; A/B=544-626.
DR   PDB; 3KUT; X-ray; 1.50 A; A/B=544-626.
DR   PDB; 3PKN; X-ray; 1.80 A; A=544-626.
DR   PDB; 3PTH; X-ray; 1.70 A; A=543-621.
DR   PDB; 4F02; X-ray; 2.00 A; A/D=1-190.
DR   PDB; 4F25; X-ray; 1.90 A; A=99-199.
DR   PDB; 4F26; X-ray; 2.00 A; A=99-199.
DR   PDB; 5DX1; X-ray; 1.93 A; F/G/H/I=449-466.
DR   PDB; 5DX8; X-ray; 1.94 A; E/F/G/H=449-466.
DR   PDB; 5DXA; X-ray; 2.07 A; F/G/I=449-466.
DR   PDB; 5LGP; X-ray; 2.04 A; E/F/G/H=447-458.
DR   PDB; 5LGQ; X-ray; 2.11 A; E/F/G/H=456-466.
DR   PDB; 5LGR; X-ray; 2.00 A; E/F/G/H=447-458.
DR   PDB; 5LGS; X-ray; 2.10 A; E/F/G/H=456-464.
DR   PDBsum; 1CVJ; -.
DR   PDBsum; 1G9L; -.
DR   PDBsum; 1JGN; -.
DR   PDBsum; 1JH4; -.
DR   PDBsum; 2K8G; -.
DR   PDBsum; 2RQG; -.
DR   PDBsum; 2RQH; -.
DR   PDBsum; 2X04; -.
DR   PDBsum; 3KTP; -.
DR   PDBsum; 3KTR; -.
DR   PDBsum; 3KUI; -.
DR   PDBsum; 3KUJ; -.
DR   PDBsum; 3KUR; -.
DR   PDBsum; 3KUS; -.
DR   PDBsum; 3KUT; -.
DR   PDBsum; 3PKN; -.
DR   PDBsum; 3PTH; -.
DR   PDBsum; 4F02; -.
DR   PDBsum; 4F25; -.
DR   PDBsum; 4F26; -.
DR   PDBsum; 5DX1; -.
DR   PDBsum; 5DX8; -.
DR   PDBsum; 5DXA; -.
DR   PDBsum; 5LGP; -.
DR   PDBsum; 5LGQ; -.
DR   PDBsum; 5LGR; -.
DR   PDBsum; 5LGS; -.
DR   ProteinModelPortal; P11940; -.
DR   SMR; P11940; -.
DR   BioGrid; 117939; 251.
DR   CORUM; P11940; -.
DR   DIP; DIP-31613N; -.
DR   ELM; P11940; -.
DR   IntAct; P11940; 132.
DR   MINT; P11940; -.
DR   STRING; 9606.ENSP00000313007; -.
DR   BindingDB; P11940; -.
DR   ChEMBL; CHEMBL1293286; -.
DR   iPTMnet; P11940; -.
DR   PhosphoSitePlus; P11940; -.
DR   SwissPalm; P11940; -.
DR   BioMuta; PABPC1; -.
DR   DMDM; 3183544; -.
DR   EPD; P11940; -.
DR   MaxQB; P11940; -.
DR   PaxDb; P11940; -.
DR   PeptideAtlas; P11940; -.
DR   PRIDE; P11940; -.
DR   DNASU; 26986; -.
DR   Ensembl; ENST00000318607; ENSP00000313007; ENSG00000070756. [P11940-1]
DR   GeneID; 26986; -.
DR   KEGG; hsa:26986; -.
DR   UCSC; uc003yjs.2; human. [P11940-1]
DR   CTD; 26986; -.
DR   DisGeNET; 26986; -.
DR   EuPathDB; HostDB:ENSG00000070756.13; -.
DR   GeneCards; PABPC1; -.
DR   HGNC; HGNC:8554; PABPC1.
DR   HPA; CAB011536; -.
DR   HPA; HPA045423; -.
DR   HPA; HPA067156; -.
DR   MIM; 604679; gene.
DR   neXtProt; NX_P11940; -.
DR   OpenTargets; ENSG00000070756; -.
DR   PharmGKB; PA32880; -.
DR   eggNOG; KOG0123; Eukaryota.
DR   eggNOG; ENOG410XR5X; LUCA.
DR   GeneTree; ENSGT00760000118913; -.
DR   HOGENOM; HOG000217922; -.
DR   HOVERGEN; HBG002295; -.
DR   InParanoid; P11940; -.
DR   KO; K13126; -.
DR   OMA; RAAYYPA; -.
DR   OrthoDB; EOG091G03ZE; -.
DR   PhylomeDB; P11940; -.
DR   TreeFam; TF300458; -.
DR   Reactome; R-HSA-156827; L13a-mediated translational silencing of Ceruloplasmin expression.
DR   Reactome; R-HSA-429947; Deadenylation of mRNA.
DR   Reactome; R-HSA-450408; AUF1 (hnRNP D0) binds and destabilizes mRNA.
DR   Reactome; R-HSA-72649; Translation initiation complex formation.
DR   Reactome; R-HSA-9010553; Regulation of expression of SLITs and ROBOs.
DR   Reactome; R-HSA-975956; Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC).
DR   Reactome; R-HSA-975957; Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC).
DR   SIGNOR; P11940; -.
DR   ChiTaRS; PABPC1; human.
DR   EvolutionaryTrace; P11940; -.
DR   GeneWiki; PABPC1; -.
DR   GenomeRNAi; 26986; -.
DR   PMAP-CutDB; P11940; -.
DR   PRO; PR:P11940; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000070756; -.
DR   CleanEx; HS_PABPC1; -.
DR   ExpressionAtlas; P11940; baseline and differential.
DR   Genevisible; P11940; HS.
DR   GO; GO:0071013; C:catalytic step 2 spliceosome; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB.
DR   GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0010494; C:cytoplasmic stress granule; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0030529; C:intracellular ribonucleoprotein complex; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0003730; F:mRNA 3'-UTR binding; IDA:UniProtKB.
DR   GO; GO:0008143; F:poly(A) binding; IDA:MGI.
DR   GO; GO:0008266; F:poly(U) RNA binding; IDA:MGI.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IDA:CAFA.
DR   GO; GO:0008494; F:translation activator activity; TAS:UniProtKB.
DR   GO; GO:0031047; P:gene silencing by RNA; ISS:UniProtKB.
DR   GO; GO:0006378; P:mRNA polyadenylation; TAS:UniProtKB.
DR   GO; GO:0000398; P:mRNA splicing, via spliceosome; IC:UniProtKB.
DR   GO; GO:0048255; P:mRNA stabilization; TAS:UniProtKB.
DR   GO; GO:2000623; P:negative regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay; IDA:UniProtKB.
DR   GO; GO:0000184; P:nuclear-transcribed mRNA catabolic process, nonsense-mediated decay; TAS:Reactome.
DR   GO; GO:0000289; P:nuclear-transcribed mRNA poly(A) tail shortening; TAS:Reactome.
DR   GO; GO:1900153; P:positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay; ISS:UniProtKB.
DR   GO; GO:0060213; P:positive regulation of nuclear-transcribed mRNA poly(A) tail shortening; ISS:UniProtKB.
DR   GO; GO:0045070; P:positive regulation of viral genome replication; IMP:UniProtKB.
DR   GO; GO:0043488; P:regulation of mRNA stability; TAS:Reactome.
DR   GO; GO:0006413; P:translational initiation; TAS:Reactome.
DR   Gene3D; 3.30.70.330; -; 4.
DR   InterPro; IPR012677; Nucleotide-bd_a/b_plait_sf.
DR   InterPro; IPR036053; PABP-dom.
DR   InterPro; IPR006515; PABP_1234.
DR   InterPro; IPR002004; PABP_HYD.
DR   InterPro; IPR035979; RBD_domain_sf.
DR   InterPro; IPR000504; RRM_dom.
DR   InterPro; IPR003954; RRM_dom_euk.
DR   Pfam; PF00658; PABP; 1.
DR   Pfam; PF00076; RRM_1; 4.
DR   SMART; SM00517; PolyA; 1.
DR   SMART; SM00360; RRM; 4.
DR   SMART; SM00361; RRM_1; 3.
DR   SUPFAM; SSF54928; SSF54928; 2.
DR   SUPFAM; SSF63570; SSF63570; 1.
DR   TIGRFAMs; TIGR01628; PABP-1234; 1.
DR   PROSITE; PS51309; PABC; 1.
DR   PROSITE; PS50102; RRM; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Methylation; mRNA processing;
KW   mRNA splicing; Nonsense-mediated mRNA decay; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; RNA-binding; Spliceosome.
FT   CHAIN         1    636       Polyadenylate-binding protein 1.
FT                                /FTId=PRO_0000081698.
FT   DOMAIN       11     89       RRM 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00176}.
FT   DOMAIN       99    175       RRM 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00176}.
FT   DOMAIN      191    268       RRM 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00176}.
FT   DOMAIN      294    370       RRM 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00176}.
FT   DOMAIN      542    619       PABC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00641}.
FT   REGION      166    289       CSDE1-binding.
FT   COMPBIAS    495    501       Poly-Ala.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES     299    299       N6-methyllysine. {ECO:0000269|Ref.7}.
FT   MOD_RES     315    315       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     319    319       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     385    385       Omega-N-methylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     419    419       Omega-N-methylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     432    432       Omega-N-methylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     436    436       Omega-N-methylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     455    455       Omega-N-methylated arginine; by CARM1;
FT                                partial. {ECO:0000305|PubMed:11850402}.
FT   MOD_RES     460    460       Omega-N-methylated arginine; by CARM1;
FT                                partial. {ECO:0000305|PubMed:11850402}.
FT   MOD_RES     475    475       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:P29341}.
FT   MOD_RES     481    481       Omega-N-methylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     493    493       Asymmetric dimethylarginine; alternate.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     493    493       Dimethylated arginine; alternate.
FT                                {ECO:0000269|Ref.6, ECO:0000269|Ref.7}.
FT   MOD_RES     493    493       Omega-N-methylarginine; alternate.
FT                                {ECO:0000244|PubMed:24129315,
FT                                ECO:0000269|Ref.6, ECO:0000269|Ref.7}.
FT   MOD_RES     506    506       Omega-N-methylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     512    512       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     518    518       Omega-N-methylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   VAR_SEQ     447    535       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.5}.
FT                                /FTId=VSP_009846.
FT   MUTAGEN     455    455       R->A: Greatly reduces methylation by
FT                                CARM1 (in vitro); when associated with A-
FT                                460. {ECO:0000269|PubMed:11850402}.
FT   MUTAGEN     460    460       R->A: Greatly reduces methylation by
FT                                CARM1 (in vitro); when associated with A-
FT                                455. {ECO:0000269|PubMed:11850402}.
FT   CONFLICT    211    213       Missing (in Ref. 1; CAA68428).
FT                                {ECO:0000305}.
FT   CONFLICT    410    410       M -> I (in Ref. 5; CAA88401).
FT                                {ECO:0000305}.
FT   CONFLICT    428    428       I -> V (in Ref. 1; CAA68428).
FT                                {ECO:0000305}.
FT   STRAND       12     17       {ECO:0000244|PDB:4F02}.
FT   HELIX        24     31       {ECO:0000244|PDB:4F02}.
FT   HELIX        32     34       {ECO:0000244|PDB:4F02}.
FT   STRAND       37     44       {ECO:0000244|PDB:4F02}.
FT   TURN         46     48       {ECO:0000244|PDB:4F02}.
FT   STRAND       51     61       {ECO:0000244|PDB:4F02}.
FT   HELIX        62     72       {ECO:0000244|PDB:4F02}.
FT   STRAND       83     86       {ECO:0000244|PDB:4F02}.
FT   HELIX        92     96       {ECO:0000244|PDB:4F02}.
FT   STRAND      100    105       {ECO:0000244|PDB:4F25}.
FT   HELIX       112    119       {ECO:0000244|PDB:4F25}.
FT   HELIX       120    122       {ECO:0000244|PDB:4F25}.
FT   STRAND      125    133       {ECO:0000244|PDB:4F25}.
FT   STRAND      136    146       {ECO:0000244|PDB:4F25}.
FT   HELIX       148    158       {ECO:0000244|PDB:4F25}.
FT   STRAND      161    163       {ECO:0000244|PDB:2K8G}.
FT   STRAND      169    174       {ECO:0000244|PDB:4F25}.
FT   HELIX       176    183       {ECO:0000244|PDB:4F02}.
FT   HELIX       547    551       {ECO:0000244|PDB:3KUJ}.
FT   HELIX       555    557       {ECO:0000244|PDB:3KUJ}.
FT   HELIX       558    573       {ECO:0000244|PDB:3KUJ}.
FT   TURN        575    577       {ECO:0000244|PDB:3KUJ}.
FT   HELIX       578    585       {ECO:0000244|PDB:3KUJ}.
FT   HELIX       590    598       {ECO:0000244|PDB:3KUJ}.
FT   HELIX       600    619       {ECO:0000244|PDB:3KUJ}.
FT   TURN        623    625       {ECO:0000244|PDB:1JGN}.
FT   STRAND      628    630       {ECO:0000244|PDB:1G9L}.
SQ   SEQUENCE   636 AA;  70671 MW;  2EB1B02A346132EE CRC64;
     MNPSAPSYPM ASLYVGDLHP DVTEAMLYEK FSPAGPILSI RVCRDMITRR SLGYAYVNFQ
     QPADAERALD TMNFDVIKGK PVRIMWSQRD PSLRKSGVGN IFIKNLDKSI DNKALYDTFS
     AFGNILSCKV VCDENGSKGY GFVHFETQEA AERAIEKMNG MLLNDRKVFV GRFKSRKERE
     AELGARAKEF TNVYIKNFGE DMDDERLKDL FGKFGPALSV KVMTDESGKS KGFGFVSFER
     HEDAQKAVDE MNGKELNGKQ IYVGRAQKKV ERQTELKRKF EQMKQDRITR YQGVNLYVKN
     LDDGIDDERL RKEFSPFGTI TSAKVMMEGG RSKGFGFVCF SSPEEATKAV TEMNGRIVAT
     KPLYVALAQR KEERQAHLTN QYMQRMASVR AVPNPVINPY QPAPPSGYFM AAIPQTQNRA
     AYYPPSQIAQ LRPSPRWTAQ GARPHPFQNM PGAIRPAAPR PPFSTMRPAS SQVPRVMSTQ
     RVANTSTQTM GPRPAAAAAA ATPAVRTVPQ YKYAAGVRNP QQHLNAQPQV TMQQPAVHVQ
     GQEPLTASML ASAPPQEQKQ MLGERLFPLI QAMHPTLAGK ITGMLLEIDN SELLHMLESP
     ESLRSKVDEA VAVLQAHQAK EAAQKAVNSA TGVPTV
//
